Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
 Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
Overall, the AIM All-Shares index had a positive week, with a more than 2% increase in share price, outperforming the FTSE 100. Friday’s closing bell, the FTSE 100 resumed its
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s
The AIM-All Share Index, which rose by 0.6% to 804 points, made only slight gains across the wider market. However, the FTSE 100’s blue-chip companies surged 3% to 7,628 points
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Significant milestones reached, well capitalised and positioned for future growth
As far as the small caps area is concerned, things remained tough work. Apart from bears enjoying the pain and occasionally the failures of others, to offset their own failings,
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
POLB 001 patent portfolio strengthened through granting of US patent
London’s results season is still underway with life insurers Aviva and L&G, bookmaker Entain, cybersecurity specialist Darktrace, and sausage roll maker Greggs all set to release results this week.
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza